NeoGenomics, Inc.

    Jurisdiction
    United States
    ISIN
    US64049M2098 (NEO)
    Sectors
    1. Healthcare
    2. Medical - Diagnostics & Research

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    5 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    4 / 7

    Profile

    NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. Read full profile

    Fundamentals

    Net revenue
    €587.84M
    Gross margin
    43.9%
    EBIT
    -€98.13M
    EBIT margin
    -16.7%
    Net income
    -€88.74M
    Net margin
    -15.1%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €680.34M +15.7% -€62.39M -29.7%
    €739.68M +8.7% -€42.88M -31.3%
    €791.41M +7.0% -€40.77M -4.9%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    Last dividend amount
    $0.40
    Ex date
    Payment date

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Sherman Jeffrey Scott Chief Financial Officer +20K $5.62 +$112.40K
    Zook Anthony P. Chief Executive Officer +18K $5.58 +$99.88K

    Congress transactions

    Name Transaction date Value
    Gilbert Cisneros June 6, 2025 $1.00K–$15.00K

    Earnings Calls

    Add to watchlist

    Notifications